Human Genome Epidemiology Literature Finder
|
Records 1 - 15 (of 15 Records) |
| Query Trace: Colorectal Neoplasms and CYP3A4[original query] |
|---|
| Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. Journal of the National Cancer Institute 2004 Nov 96 (21): 1585-92. Mathijssen Ron H J, de Jong Floris A, van Schaik Ron H N, Lepper Erin R, Friberg Lena E, Rietveld Trinet, de Bruijn Peter, Graveland Wilfried J, Figg William D, Verweij Jaap, Sparreboom Al |
| A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. Pharmacogenetics and genomics 2005 Aug 15 (8): 535-46. Landi Stefano, Gemignani Federica, Moreno Victor, Gioia-Patricola Lydie, Chabrier Amélie, Guino Elisabeth, Navarro Matilde, de Oca Javier, Capellà Gabriel, Canzian Federico, |
| Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk. BMC cancer 2007 7 (1): 123. Bethke Lara, Webb Emily, Sellick Gabrielle, Rudd Matthew, Penegar Stephen, Withey Laura, Qureshi Mobshra, Houlston Richa |
| Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients. BMC cancer 2007 7 (1): 118. Gervasini Guillermo, García-Martín Elena, Ladero José M, Pizarro Rosa, Sastre Javier, Martínez Carmen, García Monserrat, Diaz-Rubio Manuel, Agúndez José A |
| Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. British journal of cancer 2008 Oct 99 (8): 1239-45. Rouits E, Charasson V, Pétain A, Boisdron-Celle M, Delord J-P, Fonck M, Laurand A, Poirier A-L, Morel A, Chatelut E, Robert J, Gamelin |
| Modification of menopausal hormone therapy-associated colorectal cancer risk by polymorphisms in sex steroid signaling, metabolism and transport related genes. Endocrine-related cancer 2011 Jun 18 (3): 371-84. Rudolph Anja, Sainz Juan, Hein Rebecca, Hoffmeister Michael, Frank Bernd, Försti Asta, Brenner Hermann, Hemminki Kari, Chang-Claude Jen |
| Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk. Endocrine-related cancer 2011 Apr 18 (2): 265-76. Sainz J, Rudolph A, Hein R, Hoffmeister M, Buch S, von Schönfels W, Hampe J, Schafmayer C, Völzke H, Frank B, Brenner H, Försti A, Hemminki K, Chang-Claude |
| Genetic variation in vitamin D-related genes and risk of colorectal cancer in African Americans. Cancer causes & control : CCC 2014 May 25 (5): 561-70. Pibiri Fabio, Kittles Rick A, Sandler Robert S, Keku Temitope O, Kupfer Sonia S, Xicola Rosa M, Llor Xavier, Ellis Nathan |
| Irinotecan-induced muscle twitching from a possible drug interaction: A case report. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2017 7 24 (7): 555-560. Peters S S, Bettinger J, Philip J, Karhan B, Wrzesinski S |
| Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan-induced severe toxicity. British journal of clinical pharmacology 2018 Mar . Riera Pau, Salazar Juliana, Virgili Anna C, Tobeña María, Sebio Ana, Gallano Pía, Barnadas Agustí, Páez Dav |
| Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers. Therapeutic advances in medical oncology 2019 6 11 1758835919846421. Bruera Gemma, Massacese Silvia, Pepe Francesco, Malapelle Umberto, Dal Mas Antonella, Ciacco Eugenio, Calvisi Giuseppe, Troncone Giancarlo, Simmaco Maurizio, Ricevuto Enri |
| Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy. Scientific reports 2020 Aug 10 (1): 13486. Atasilp Chalirmporn, Chansriwong Phichai, Sirachainan Ekaphop, Reungwetwattana Thanyanan, Sirilerttrakul Suwannee, Chamnanphon Monpat, Puangpetch Apichaya, Sukasem Chonlaph |
| Is OPRM1 genotype a valuable predictor of VAS in patients undergoing laparoscopic radical resection of colorectal cancer with fentanyl? BMC anesthesiology 2023 5 23 (1): 173. Yan Zhou, Lei Cao, Yihui Yang, Yaoyi Gao, Yihao Li, Beili Wang, Baishen Pan, Jian Huang, Wei G |
| Impact of Posaconazole and Diltiazem on Pharmacokinetics of Encorafenib, a BRAF V600 Kinase Inhibitor for Melanoma and Colorectal Cancer with BRAF Mutations. Clinical and translational science 2023 10 . Erik Hahn, Renae Chavira, Lance Wollenberg, Weiwei Tan, Micaela B Red |
| Novel drug resistance mechanisms and drug targets in BRAF-mutated peritoneal metastasis from colorectal cancer. Journal of translational medicine 2024 7 22 (1): 646. Christin Lund-Andersen, Annette Torgunrud, Chakravarthi Kanduri, Vegar J Dagenborg, Ida S Frøysnes, Mette M Larsen, Ben Davidson, Stein G Larsen, Kjersti Flatma |
- Page last reviewed:Feb 1, 2024
- Content source: